68 Ga-PSMA PET/CT for primary NM staging of high-risk prostate cancer
暂无分享,去创建一个
K. D. Sørensen | M. Borre | B. Ulhøi | K. Bouchelouche | M. Jochumsen | J. Fredsøe | Søren Klingenberg | Jacob Fredsøe
[1] N. Lawrentschuk,et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study , 2020, The Lancet.
[2] S. Padma,et al. In primary lymph nodal staging of patients with high-risk and intermediate-risk prostate cancer, how critical is the role of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography? , 2019, Nuclear medicine communications.
[3] D. Murphy,et al. The role of prostate-specific membrane antigen PET/computed tomography in primary staging of prostate cancer. , 2019, Current opinion in urology.
[4] H. Wester,et al. PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy. , 2019, Seminars in nuclear medicine.
[5] B. Hadaschik,et al. Molecular Imaging for Primary Staging of Prostate Cancer. , 2019, Seminars in nuclear medicine.
[6] R. Hicks,et al. Molecular Imaging of Recurrent and Metastatic Prostate Cancer. , 2019, Seminars in nuclear medicine.
[7] K. Pienta,et al. Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer: An Update on Important Pitfalls. , 2019, Seminars in nuclear medicine.
[8] B. Delahunt,et al. Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with 68Ga-PSMA Positron Emission Tomography/Computerized Tomography Compared to Histological Correlation of Pelvic Lymph Node Pathology , 2019, The Journal of urology.
[9] T. Esen,et al. Can SUVmax values of Ga-68-PSMA PET/CT scan predict the clinically significant prostate cancer? , 2018, Nuclear medicine communications.
[10] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[11] Hiroyuki Takahashi,et al. Anatomical localization and clinical impact of sentinel lymph nodes based on patterns of pelvic lymphatic drainage in clinically localized prostate cancer , 2018, The Prostate.
[12] Steven P Rowe,et al. PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA-targeted PET Imaging Studies. , 2017, European urology.
[13] Frederik L. Giesel,et al. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT , 2017, The Journal of Nuclear Medicine.
[14] N. Lawrentschuk,et al. (68)GA-PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) POSITRON EMISSION TOMOGRAPHY (PET) FOR PRIMARY STAGING OF HIGH RISK PROSTATE CANCER: A SYSTEMATIC REVIEW , 2017 .
[15] H. G. van der Poel,et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. , 2017, European urology.
[16] Clemens Decristoforo,et al. 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[17] H. Heinzer,et al. Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. , 2016, European urology.
[18] B. Delahunt,et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System , 2015, The American journal of surgical pathology.
[19] A. Haese*,et al. PSMA Expression is Highly Homogenous in Primary Prostate Cancer , 2015, Applied immunohistochemistry & molecular morphology : AIMM.
[20] S. Gültekin,et al. A narrowing range of bone scan in newly diagnosed prostate cancer patients: A retrospective comparative study , 2015, Urology annals.
[21] J. Ciezki,et al. Comparison of biochemical relapse-free survival between primary Gleason score 3 and primary Gleason score 4 for biopsy Gleason score 7 prostate cancer. , 2009, International journal of radiation oncology, biology, physics.
[22] F. Montorsi,et al. Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer , 2006, BJU international.
[23] A W Partin,et al. Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. , 2000, Urology.
[24] S B Malkowicz,et al. Biochemical Outcome After Radical Prostatectomy , External Beam Radiation Therapy , or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer , 2000 .